A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate

Journal of Neurochemistry

Volumn 94, Issue 2, 2005, Pages 352-359

  Chen, Rong ^a   Han, Dawn D ^a   Gu, Howard H ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Cocaine; Dopamine transporter; Methylphenidate; Random mutagenesis

Indexed keywords

AMPHETAMINE; COCAINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; METHYLPHENIDATE; PHENYLALANINE; PSYCHOSTIMULANT AGENT;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; COCAINE DEPENDENCE; DOPAMINE UPTAKE; DRUG DEPENDENCE; DRUG POTENCY; DRUG SENSITIVITY; GENE MUTATION; MOUSE; MUTAGENESIS; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SYNAPTIC INHIBITION; WILD TYPE;

AMINO ACID SUBSTITUTION; AMPHETAMINE; ANIMALS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CELL LINE; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HAPLORHINI; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHYLPHENIDATE; MICE; MICE, KNOCKOUT; MUTAGENESIS; MUTATION; NERVE TISSUE PROTEINS; PHENYLALANINE; PROTEIN STRUCTURE, TERTIARY; RADIOLIGAND ASSAY; TRANSFECTION; TRITIUM;

EID: 22244444131     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03199.x     Document Type: Article

References (27)

1. Amara S. G. and Kuhar M. J. (1993) Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16, 73-93.
2. Barker E. L., Moore K. R., Rakhshan F. and Blakely R. D. (1999) Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J. Neurosci. 19, 4705-4717.
3. Bengel D., Murphy D. L., Andrews A. M., Wichems C. H., Feltner D., Heils A., Mossner R., Westphal H. and Lesch K. P. (1998) Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethampbetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol. Pharmacol. 53, 649-655.
4. Blakely R. D., Clark J. A., Rudnick G. and Amara S. G. (1991) Vaccinia-T7 RNA polymerase expression system: evaluation for the expression cloning of plasma membrane transporters. Anal Biochem. 194, 302-308.
5. Carroll F. I., Lewin A. H., Boja J. W. and Kuhar M. J. (1992) Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J. Med. Chem. 35, 969-981.
6. Chen N., Vaughan R. A. and Reith M. E. (2001) The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis. J. Neurochem. 77, 1116-1127.
7. Giros B., Wang Y. M., Suter S., McLeskey S. B., Pifl C. and Caron M. (1994) Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 268, 15 985-15 988.
8. Giros B., Jaber M., Jones S. R., Wightman R. M. and Caron M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
9. Granas C., Ferrer J., Loland C. J., Javitch J. A. and Gether U. (2003) N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization. J. Biol. Chem. 278, 4990-5000.
10. Gu H. H., Wall S. C. and Rudmck G. (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269, 7124-7130.
11. Gu H. H., Ahn J., Caplan M. J., Blakely R. D., Levey A. I. and Rudnick G. (1996) Cell-specific sorting of biogenic amine transporters expressed in epithelial cells. J. Biol. Chem. 271, 18 100-18 106.
12. Kitayama S., Shimada S., Xu H., Markham L., Donovan D. M. and Uhl G. R. (1992) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl Acad. Sci. USA 89, 7782-7785.
13. Lin Z, and Uhl G. R. (2002) Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Mol. Pharmacol. 61, 885-891.
14. Lin Z., Wang W., Kopajtic T., Revay R. S. and Uhl G. R. (1999) Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol. Pharmacol. 56, 434-447.
15. Lin Z., Itokawa M. and Uhl G. R. (2000a) Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression. Faseb J. 14, 715-728.
16. Lin Z., Wang W. and Uhl G. R. (200Ob) Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains. Mol. Pharmacol. 58, 1581-1592.
17. Ritz M. C. and Kuhar M. J. (1993) Psychostimulant drugs and a dopamine hypothesis regarding addiction: update on recent research. Biochem. Soc. Symp. 59, 51-64.
18. Ritz M. C., Lamb R. J., Goldberg S. R. and Kuhar M. J. (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237, 1219-1223.
19. Rocha B. A., Fumagalli F., Gainetdinov R. R., Jones S. R., Ator R., Giros B., Miller G. W. and Caron M. G. (1998) Cocaine self-administration in dopamine-transporter knockout mice[see comments] [published erratum appears in Nat. Neurosci. 1998 August; 1 (4): 330]. Nat. Neurosci. 1, 132-137.
20. Sora I., Wichems C., Takahashi N., Li X. F., Zeng Z., Revay R., Lesen K. P., Murphy D. L. and Uhl G. R. (1998) Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl Acad. Sci. USA 95, 7699-7704.
21. Surratt C. K., Wang J. B., Yuhasz S., Amzel M., Kwon H. M., Handler J. S. and Uhl G. R. (1993) Sodium- and chloride-dependent transporters in brain, kidney, and gut: lessons from complementary DNA cloning and structure-function studies. Curr. Opin. Nephrol. Hypertens. 2, 744-760.
22. Torres G. E., Carneiro A., Seamans K., Fiorentini C., Sweeney A., Yao W. D. and Caron M. G. (2003) Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J. Biol. Chem. 278, 2731-2739.
23. Wang Y. M., Xu F., Gainetdinov R. R. and Caron M. G. (1999) Genetic approaches to studying norepinephrine function: knockout of the mouse norepinephrine transporter gene. Biol. Psychiat. 46, 1124-1130.
24. Wayment H., Meiergerd S. M. and Schenk J. O. (1998) Relationships between the catechol substrate binding site and amphetamine, cocaine, and mazindol binding sites in a kinetic model of the striatal transporter of dopamine in vitro. J. Neurochem. 70, 1941-1949.
25. Wayment H. K., Deutsch H., Schweri M. M. and Schenk J. O. (1999) Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists? J. Neurochem. 72, 1266-1274.
26. Wu X. and Gu H. H. (2003) Cocaine affinity decreased by mutations of aromatic residue phenylalanine 105 in the transmembrane domain 2 of dopamine transporter. Mol. Pharmacol. 63, 653-658.
27. Wu X. H. and Gu H. H. (1999) Molecular cloning of the mouse dopamine transporter and pharmacological comparison with the human homologue. Gene 233, 163-170.